AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05890885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham - Real left prefrontal tDCS
Description: Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
Study NCT04750044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed refeeding
Description: In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
Study NCT06061575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: fever will be managed with acetaminophen
Study NCT06061575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: fever will be managed with ibuprofen
Study NCT05903937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Administered via hepatic arterial infusion (HAI)
Study NCT05903937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered via isolated hepatic perfusion
Study NCT05522738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination: Fruquintinib + FOLFIRI
Description: Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w
Study NCT06326021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous FL-33 CAR T therapy
Description: Autologous FL-33 CAR T cells are infused intravenously.
Study NCT06326021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prior-HSCT donor-derived FL-33 CAR T therapy
Description: Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
Study NCT06073678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Irradiation with red laser on palate wound each 48h for 4 sessions.
Study NCT06073678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protection with surgical dressing
Description: Protection of the palatal wound with surgical dressing for 7 days
Study NCT06607991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Treatment
Description: Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Study NCT06681649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge
Study NCT05233397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
Study NCT06626230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin C3 Complex powder: Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period.~Escalating doses
Study NCT06629688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
Study NCT05766969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/PEA
Description: A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
Study NCT05766969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study NCT05903937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low-dose, administered s.c.
Study NCT05758597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remazolam besylate
Description: Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
Study NCT05758597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
Study NCT05316246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin in Combination with Tislelizumab
Description: Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
Study NCT06098209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
Study NCT06709079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)
Description: Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
Study NCT06710080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Description: Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
Study NCT06220565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor and wearable device Graded Exercise
Description: The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management.
Study NCT06220565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: exercise
Study NCT06220565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise
Study NCT06098209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patient will receive propofol 0.3-4 mg/kg/h.
Study NCT05094752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
Study NCT05094752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
Study NCT06710080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel crown
Description: Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown
Description: Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
Study NCT04873531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery.
Study NCT04873531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery.
Study NCT05028231 — intervention group
Intervention type: PROCEDURE
Intervention: Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy
Description: Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
Study NCT03602040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PISICC
Description: PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c).
Study NCT05208658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Classical Vision Therapy Treatment
Description: Do classical vision therapy treatment for improve vergence
Study NCT05208658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Classical Vision Therapy Treatment
Description: Do classical vision therapy treatment for improve vergence
Study NCT05208658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control: Eye Movement Therapy Treatment
Description: Do eye movement therapy treatment in order not to improve vergence
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia crown
Description: Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioflx crown
Description: Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
Study NCT06706167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioflx crown
Description: Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
Study NCT06715384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polyp size measurement using autonomous AI measurement or AI-assisted human measurement with the CAM system
Description: The study of real-time polyp size measurement using the CAM system will be conducted in two phases. Phase I (pilot phase, n=24 polyps, about 27 patients) will be used to assess the feasibility of applying the CAM system in real-time in a clinical video in order to obtain pilot data on the relative accuracy of assessing polyp sizes using autonomous AI measurement and AI-assisted human measurement and to determine the relative accuracy of assessing polyp size in Phase II of the study ( Randomized Controlled Trial) to assess the sample size and reference standards for the CAM system. The sample size for the second phase of the randomized controlled trial (comparing AI-assisted human measurement to non-scaled device) will be based on pilot data in order to compare the relative accuracy of polyp size measurement with AI-assisted human measurement versus non-scaled device in clinical practice.
Study NCT06716359 — intervention group
Intervention type: OTHER
Intervention: Observational study without intervention
Description: Observational study without intervention
Study NCT06719401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Foot Chest Compression
Description: Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.
Study NCT06719401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand Chest Compression
Description: Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.
Study NCT06717984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy, Mastectomy, Histopathology
Description: Biopsy:~This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes.~Mastectomy:~This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer.~Histopathology:~This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions.
Study NCT06718842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking free online supervised program
Description: this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
Study NCT06220565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Manual
Description: Educational Manual
Study NCT06710288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
Study NCT06710288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Dose: fixed dose of 1.2 mg subcutaneously (SC) Frequency: administered on Day 1 and Day 15 of each cycle starting at Cycle 2 (every 4 weeks) and when the last dose of M-CENK is administered, N-803 will be administered on Days 1 and 15 of the same cycle followed by 3 additional doses, 2 weeks apart (total of 5 N-803 doses).
Study NCT06710288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-CENK
Description: Dose: 0.15 to 0.75 × 109 cells per infusion intravenously (IV) Frequency: administered on Day 1 of each cycle as long as M-CENK cells are available.
Study NCT06719206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital self-management program
Description: The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
Study NCT06715111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: A study used a laser acupuncture device to deliver treatment to 27 participants in Group A. The device, was designed for high power, non-thermal treatment. The device had a Class IV- high power, non-thermal laser with a wave length of 808-905 and a 650 nm wavelength. It had an ergonomic handpiece, high efficiency aiming beam, and adjustable emission intensity range. The device also included two laser safety goggles, a touchscreen stylus, and a retractable banner. Participants were instructed to relax and accurately detect acupoints before application. The device was adjusted for safety and both participants and researchers wore laser goggles.
Study NCT06715111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional pelvic floor exercise
Description: The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.
Study NCT06715111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional pelvic floor exercise
Description: The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.